Bovine Lactoferrin and Lactoferricin, a Peptide Derived from Bovine Lactoferrin, Inhibit Tumor Metastasis in Mice
Overview
Authors
Affiliations
We investigated the effect of a bovine milk protein, lactoferrin (LF-B), and a pepsin-generated peptide of LF-B, lactoferricin (Lfcin-B), on inhibition of tumor metastasis produced by highly metastatic murine tumor cells, B16-BL6 melanoma and L5178Y-ML25 lymphoma cells, using experimental and spontaneous metastasis models in syngeneic mice. The subcutaneous (s.c.) administration of bovine apo-lactoferrin (apo-LF-B, 1 mg/mouse) and Lfcin-B (0.5 mg/mouse) 1 day after tumor inoculation significantly inhibited liver and lung metastasis of L5178Y-ML25 cells. However, human apolactoferrin (apo-LF-H) and bovine holo-lactoferrin (holo-LF-B) at the dose of 1 mg/mouse failed to inhibit tumor metastasis of L5178Y-ML25 cells. Similarly, the s.c. administration of apo-LF-B as well as Lfcin-B, but not apo-LF-H and holo-LF-B, 1 day after tumor inoculation resulted in significant inhibition of lung metastasis of B16-BL6 cells in an experimental metastasis model. Furthermore, in in vivo analysis for tumor-induced angiogenesis, both apo-LF-B and Lfcin-B inhibited the number of tumor-induced blood vessels and suppressed tumor growth on day 8 after tumor inoculation. However, in a long-term analysis of tumor growth for up to 21 days after tumor inoculation, single administration of apo-LF-B significantly suppressed the growth of B16-BL6 cells throughout the examination period, whereas Lfcin-B showed inhibitory activity only during the early period (8 days). In spontaneous metastasis of B16-BL6 melanoma cells, multiple administration of both apo-LF-B and Lfcin-B into tumor-bearing mice significantly inhibited lung metastasis produced by B16-BL6 cells, though only apo-LF-B exhibited an inhibitory effect on tumor growth at the time of primary tumor amputation (on day 21) after tumor inoculation. These results suggest that apo-LF-B and Lfcin-B inhibit tumor metastasis through different mechanisms, and that the inhibitory activity of LF-B on tumor metastasis may be related to iron (Fe3+)-saturation.
Albumin fusion with human lactoferrin shows enhanced inhibition of cancer cell migration.
Nopia H, Kurimoto D, Sato A Biometals. 2022; 36(3):629-638.
PMID: 36167912 DOI: 10.1007/s10534-022-00447-9.
Hsieh C, Wang T, Tung B, Liu H, Yeh L, Hsu K Molecules. 2022; 27(9).
PMID: 35566188 PMC: 9101267. DOI: 10.3390/molecules27092839.
Guerra J, Cardenas A, Ochoa-Zarzosa A, Meza J, Umana Perez A, Fierro-Medina R RSC Adv. 2022; 9(36):20497-20504.
PMID: 35515557 PMC: 9065741. DOI: 10.1039/c9ra04145a.
Cell-penetrating peptides improve pharmacokinetics and pharmacodynamics of anticancer drugs.
Rusiecka I, Gagalo I, Kocic I Tissue Barriers. 2021; 10(1):1965418.
PMID: 34402743 PMC: 8794253. DOI: 10.1080/21688370.2021.1965418.
Rahman R, Fonseka A, Sua S, Ahmad M, Rajendran R, Ambu S J Cell Mol Med. 2021; 25(15):7181-7189.
PMID: 34236134 PMC: 8335703. DOI: 10.1111/jcmm.16748.